Price
$24.51
Increased by +0.49%
Dollar Volume
2.06 M
ADR%
8.5
Earnings Report Date (estimate)
Nov 14, 22 (N/A)
Market Cap.
603.07 M
Shares Float
4.61 M
Shares Outstanding
24.61 M
Beta
0.00
Price / Earnings
0.85
BPR
310.81
20D Range
21.48 27.37
50D Range
14.33 30.79
200D Range
10.52 30.79
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Nov 14, 22 -0.56
Decreased by -115.38%
-0.50
Decreased by -12.00%
Aug 15, 22 -0.49
Increased by +97.94%
-0.45
Decreased by -8.89%
May 16, 22 -0.45 -0.28
Decreased by -60.71%
Mar 30, 22 -0.35 -0.31
Decreased by -12.90%
Nov 15, 21 -0.26 -0.26
Aug 16, 21 -23.80 -0.16
Decreased by -14.78 K%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 22 0.00
Decreased by N/A%
-13.59 M
Decreased by -119.73%
Decreased by N/A%
Decreased by N/A%
Jun 30, 22 0.00
Decreased by N/A%
-11.99 M
Decreased by -107.64%
Decreased by N/A%
Decreased by N/A%
Mar 31, 22 0.00
Decreased by N/A%
-10.91 M
Decreased by -292.30%
Decreased by N/A%
Decreased by N/A%
Dec 31, 21 0.00
Decreased by N/A%
-8.70 M
Decreased by -137.23%
Decreased by N/A%
Decreased by N/A%
Sep 30, 21 0.00
Decreased by N/A%
-6.18 M
Decreased by -168.05%
Decreased by N/A%
Decreased by N/A%
Jun 30, 21 0.00
Decreased by N/A%
-5.78 M
Decreased by -162.26%
Decreased by N/A%
Decreased by N/A%
Mar 31, 21 0.00
Decreased by N/A%
-2.78 M
Decreased by -93.66%
Decreased by N/A%
Decreased by N/A%
Dec 31, 20 0.00 - -3.67 M -
Decreased by N/A%
-
  • Top 20 ETF Stock Exposure
  • Top 20 Institutional Holders
  • Top 20 Mutual Fund Holders
Rank ETF Shares Market Value Weight % in ETF
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.